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Abstract
Background: Despite its initial positive response to hormone ablation therapy, prostate cancers invariably recur in more
aggressive, treatment resistant forms. The lack of our understanding of underlying genetic alterations for the transition from
androgen-dependent (AD) to ADI prostate cancer growth hampers our ability to develop target-driven therapeutic
strategies for the efficient treatment of ADI prostate cancer.
Methodology/Principal Findings: By screening a library of activated human kinases, we have identified TPL2, encoding a
serine/threonine kinase, as driving ADI prostate cancer growth. TPL2 activation by over-expressing either wild-type or a
constitutively activated form of TPL2 induced ADI growth, whereas the suppression of TPL2 expression and its kinase activity
in ADI prostate cancer cells inhibited cell proliferation under androgen-depleted conditions. Most importantly, TPL2 is
upregulated in ADI prostate cancers of both the Pten deletion mouse model and the clinical prostate cancer specimens.
Conclusions/Significance: Together these data suggest that TPL2 kinase plays a critical role in the promotion of ADI
prostate cancer progression. Furthermore, the suppression of TPL2 diminishes ADI prostate cancer growth and a high
frequency of TPL2 overexpression in human ADI prostate cancer samples validates TPL2 as a target for the treatment of this
deadly disease.
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Introduction
Prostate cancer affects 1 in 6 American men, with more than 2
million currently living with the disease. Surgery is effective, with
nearly 100% of the patients remaining cancer-free for several years
if the disease is detected early and the cancer cells are confined to
the prostate [1]. However, once the cancer spreads beyond the
prostate gland, the outcome is nearly always fatal. Since prostate
cancer cells require testosterone to fuel their growth and survival,
androgen-deprivation therapy has been designed to halt cancer
growth by either stopping the production of testosterone or
preventing the hormone from acting on prostate cancer cells [2].
Despite the initial positive response to hormone therapy, prostate
cancer cells invariably recur in an aggressive, androgen depletion-
independent (ADI) form. While genetic alterations associated with
the initiation and progression of prostate cancer have been
intensively studied [3,4,5,6,7], those underlying the transition from
androgen-dependent (AD) to ADI prostate cancer growth are
relatively less well understood. This lack of understanding hampers
our ability to develop target-driven therapeutic strategies for the
efficient treatment of ADI prostate cancer.
In the presence of androgen, the androgen receptor (AR)
undergoes phosphorylation, dimerization, and translocation into
the nucleus, wherein it binds to androgen response elements (ARE)
sites, resulting in the transcriptional activation of target genes [8].
However, compelling data, including RNAi knockdown and the
introduction of antagonists of the androgen receptor (AR), indicate
that AR is still necessary for ADI prostate cancer growth [9,10,11].
Therefore, under androgen-depleted conditions, ADI prostate
cancer cells appear to develop intracellular strategies that activate
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16205the AR signaling pathway. Many underlying mechanisms have
been proposed: increased AR expression through AR gene
amplification, increased AR sensitivity through enhanced AR
stability and nuclear localization, broadened AR ligand specificity
through mutations in its ligand-binding domain, and increased AR
activity through post-translational modifications [12,13,14,15,16,
17,18]. On the other hand, the activation of other signal
transduction pathways, such as BCL-2 activation, may also bypass
the requisite of AR activation for the proliferation and survival of
prostate cancer cells [19]. Finally, a preexisting subpopulation of
ADI prostate cancer cells with progenitor/stem cells traits may
become dominant under androgen-depleted conditions [20].
Many studies reveal that the activation of the RAS/RAF/
MEK/ERK pathway may be correlated with ADI prostate cancer
growth [5,13,21,22]. Recently, a genetically-engineered mouse
(GEM) model, in which the expression of a potent activator of
RAS-MAPK signaling, B-RAF
E600, is targeted to the prostate
epithelium using a tet-inducible system, developed invasive
adenocarcinoma, and this further progressed to indolent ADI
lesions after castration [23]. However, counter-intuitively, activat-
ing mutations in the RAS/RAF/MEK/ERK pathway are
infrequent in human prostate cancers, although autocrine and
paracrine growth factor loops appear to activate the pathway
[24,25]. Importantly, a recent study proposed that chromosomal
rearrangements of the RAF kinase pathway is an additional
sources of MEK/ERK signaling activation, contributing to
prostate cancer development and progression [26].
In order to identify novel kinase genes related to ADI prostate
cancer growth, we screened a library of activated human kinases.
Here, we report the identification of a serine/threonine kinase,
TPL2, as driving ADI prostate cancer growth through the
activation of the MEK/ERK signaling pathway and NF-kB. This
provides a clue for finding additional sources of MEK/ERK
pathway activation in ADI prostate cancers. Furthermore, the
suppression of TPL2 diminishes ADI prostate cancer growth and a
high frequency of TPL2 overexpression in human ADI prostate
cancer samples validates TPL2 as a target for the treatment of this
deadly disease.
Results
The Identification of TPL2, by Screening a Library of
Activated Human Kinases
To identify novel kinase genes related to ADI prostate cancer
growth, we screened a library of 354 activated human kinases
composed of 98 kinase-related open reading frames (ORFs) and
256 human kinases cloned into a Gateway-compatible retroviral
destination vector, pWN-MF-DEST, in which a myristoylation
sequence and a FLAG-epitope tag (MF) were added to the N-
termini of each introduced ORF [27]. As a readout for the
screen, we used a reporter construct containing the cis-regulatory
promoter region (5.8 kb containing an AR enhancer) of the
prostate-specific antigen (PSA) gene, which is highly expressed in
the normal prostate epithelium and in prostate tumors [28,29].
The promoter/enhancer activity may be measured by a fused
Luciferase reporter gene (Figure 1A). In order to identify possible
kinase genes able to induce the transcriptional activity of the PSA
enhancer/promoter cis-regulatory region under androgen-deplet-
ed conditions, each kinase construct, along with the reporter
plasmid, was co-transfected into individual wells of a 12-well plate
containing androgen-dependent LNCaP (AD-LNCaP) cells
grown in media supplemented with R1881, a synthetic androgen
(Figure 1A). Twenty-four hours after transfection, AD-LNCaP
cells were incubated with the medium containing 10% charcoal-
stripped fetal bovine serum (CS-FBS) without R1881. After
24 hours incubation, transcriptional activity of the PSA enhanc-
er/promoter cis-regulatory region under androgen-depleted
conditions was measured by LUCIFERASE assays. Out of 354
activated human kinase genes, the expression of TPL2 gene in
AD-LNCaP cells induced the highest level of PSA transcriptional
activity in the absence of R1881 (Figure 1B upper). As controls,
other oncogenes, such as RAF and RAS that have previously been
known to be associated with ADI prostate cancer growth, were
included [5,22,23,26,30]. Their expression indeed induced
transcriptional activity of the PSA enhancer/promoter cis-
regulatory region under androgen-depleted conditions to some
but lesser extents than TPL2. However, when tested in androgen
receptor (AR)-negative DU-145 prostate cancer cells, TPL2 did
not induce the ADI transcriptional activity, suggesting that AR
expression is necessary for the ADI transcriptional activation of
the PSA enhancer/promoter cis-regulatory region induced by
TPL2 (Figure 1B middle; please note the change in the scale of
the Y-axis). On the other hand, androgen depletion-independent
C4-2B (ADI-C4-2B) cells showed high endogenous levels of
transcriptional activity of the PSA enhancer/promoter cis-
regulatory region in the absence of R1881 (Figure 1B bottom).
These data raise the possibility that preexisting genetic and
epigenetic alterations in ADI-C4-2B cells contribute to the high
endogenous level of ADI transcriptional activity driven by the
PSA enhancer/promoter cis-regulatory region. It should be noted
the induction of transcriptional activity of the PSA enhancer/
promoter cis-regulatory region by TPL2 overexpression in AD-
LNCaP cells was more striking (greater than 20 fold) at low levels
(0.1,0.001 nM) of R1881, which is comparable to the physio-
logical levels of androgen in patients who have undergone
castration surgery (Figure 1C). Furthermore, ADI transcriptional
activation was abrogated with a TPL2 inhibitor treatment when
either with TPL2 overexpression in AD-LNCaP cells or simply
with endogenous TPL2 expression in ADI-C4-2B cells
(Figure 1D). To test the possibility that the high endogenous
level of ADI transcriptional activity of the PSA enhancer/
promoter cis-regulatory region in ADI-C4-2B cells may be due to
increased TPL2 expression, we compared the expression level of
TPL2 in AD-LNCaP and ADI-C4-2B cells. Indeed, ADI-C4-2B
cells showed higher level of TPL2 expression than in AD-LNCaP
cells (Figure S1A). Furthermore, in C4-2B cells, PSA enhancer/
promoter activity responds to low levels of exogenous TPL2
expression, but not to high levels of TPL2 expression (Figure
S1B). It is possible that high levels of TPL2 exogenous expression
in C4-2B cells, which already express a higher level of
endogenous TPL2 expression than LNCaP cells, result in adverse
effects on PSA enhancer/promoter activity. Therefore, we have
identified TPL2 as a candidate oncogene, which may be
associated with ADI prostate cancer growth.
TPL2 Activation Induces the ADI Growth of AD Prostate
Cancer Cells
To verify whether TPL2 is functionally associated with ADI
prostate cancer cell growth, we investigated the functional
consequences of the overexpression or suppression of TPL2 in
AD or ADI prostate cancer cells, respectively. Firstly, to determine
whether TPL2 overexpression is sufficient to promote ADI
prostate cancer growth, we established AD-LNCaP stable cell
lines overexpressing either N-terminally myc-tagged wild-type
[myc-TPL2 (WT)], a constitutively activated form with a deletion of
70 amino acids in its C-terminus [myc-TPL2 (DC)], or a kinase-
inactive form of TPL2 [myc-TPL2 (D270A)] using the pBabe-puro
vector (Figure 2A). The expression of each transduced gene was
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expression of myc-TPL2 (DC) constitutively activated mutant was
lower than that of myc-TPL2 (WT) and myc-TPL2 D270A mutant
despite having the highest level of phosphor-ERK, a downstream
signaling molecule (Figure 2B). To eliminate the possibility of
expression level effects, we established another set of AD-LNCaP
stable cell lines that over-express either C-terminally flag-tagged
wild-type (TPL2-wt-flag), a constitutively activated form with a
deletion of 70 amino acids in C-terminus (TPL2-delC-flag), or a
kinase-inactive form of TPL2 (TPL2-inactive-flag) using the pEF-
IRES-puro vector (Figure S2). This condition also showed the
lower expression of TPL2-delC-flag than TPL2-wt-flag and TPL2-
inactive-flag (Figure S2), suggesting that the expression of a
constitutively activated form of TPL2 above physiological levels
may have adverse effects on the cell. However, regardless TPL2
expression levels, overall LNCaP cells expressing either myc-
TPL2 (WT) or myc-TPL2 (DC) showed accelerated cell prolifer-
ation at androgen-deprived, -low, and -rich conditions compared
to LNCaP cells expressing either vector alone or myc-TPL2
(D270A) mutant (Figure 2C). In particular, LNCaP cells ex-
pressing myc-TPL2 (DC) showed statistically significant increases
in cell proliferation in comparison to control cells (LNCaP-GFP)
under the androgen-depleted condition and at low levels of R1881
(0.01 nM and 0.1 nM) at 3, 6, 9 days (*p-value ,0.05). Similar
data were obtained with stable cell lines constructed with the pEF-
IRES-puro vector (Figure S2). Therefore, these data indicate that
TPL2 activation by over-expressing either wild-type or a
constitutively activated form of TPL2 leads to the promotion of
ADI growth of AD-LNCaP cells.
The Suppression of TPL2 Expression or Inhibition of Its
Kinase Activity in ADI Prostate Cancer Cells Results in
Reduced Proliferation Phenotypes
Next, to determine whether ADI prostate cancer cells are
dependent on TPL2 for their ADI cell growth, we suppressed
TPL2 expression or activity either by shRNA-mediated knock-
down or by TPL2 inhibitor treatment, respectively. As shown in
Figure S1, TPL2 expression was is higher in ADI-C4-2B cells than
in AD-LNCaP cells. The decreased expression of TPL2 in ADI-
C4-2B cells by shRNA-mediated knockdown using the pLKO.1-
TRC vector was confirmed by western blot (Figure 3A). ADI-C4-
2B cells with a decreased expression of TPL2 showed significantly
reduced proliferation rate under androgen-depleted conditions
(Figure 3B). We confirmed these data by additional shRNA-
mediated knockdown system using the pGIPZ lentiviral vector
(Figure S3). Furthermore, the ADI cell growth of ADI-C4-2B cells
was also significantly diminished upon the treatment of a TPL2
inhibitor [Figure 3C; The 50% inhibitory concentration (IC
50)o f
4.0 mM was determined as in Figure S4]. The suppression of
MEK/ERK pathway in ADI-C4-2B cells with the treatment of
TPL2 was confirmed by western blot (Figure 3D). Together, these
data indicate that TPL2 activation is necessary for the efficient
ADI growth of ADI-C4-2B cells.
Figure 1. Identification of TPL2 as a candidate gene associated with ADI prostate cancer growth. (A) Schematic of the identification of
candidate genes that can induce the transcriptional activation of a PSA enhancer/promoter cis-regulatory region reporter construct under androgen-
depleted conditions in androgen-dependent LNCaP cells. Myr, myristoylation sequence; ARE, androgen response elements; CS-FBS, charcoal-stripped
fetal bovine serum. (B) Relative LUC activity (the PSA enhancer/promoter LUCIFERASE activity is normalized to the pGL3 beta-GALACTOSIDASE
activity) was measured after 24 hours of incubation with 10% CS-FBS without R1881 (except for the second column with 10% CS-FBS+1 nM R1881 as
a control), following co-transfection of plasmids expressing constitutively activated forms of the indicated kinase genes. The fold induction values
(relative LUC activity divided by the relative basal LUC activity of the vector control) are indicated in the graph for LNCaP cells. Relative LUC activities
upon TPL2 expression are indicated in red. Statistically significant increases in LUC activities in comparison to vector control without R1881 treatment
are marked with * (p,0.05). (C) Relative LUC activity with increasing concentration of R1881 in LNCaP cells transiently co-transfected with either
plasmids expressing myristoylated TPL2 or with empty vector. Statistically significant increases in LUC activity in comparison to each corresponding
R1881 concentration with vector control are marked with * (p,0.05). (D) Relative LUC activity with increasing concentration of TPL2 inhibitor either in
AD-LNCaP cells transiently co-transfected with plasmids expressing myristoylated TPL2 or in untransfected AI-C4-2B cells. Relative LUC activities with/
without R1881 are indicated in black as controls. Statistically significant increases in LUC activities in comparison to vector control without R1881
treatment are marked with * (p,0.05). All the experiments were performed three times with each in triplicate, and each column represents the
mean 6 standard deviation.
doi:10.1371/journal.pone.0016205.g001
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the Pten Deletion Mouse Model
Previously, it had been shown that biallelic conditional Pten
deletion in the prostate epithelium could induce adenocarcinoma
that recapitulates most of the histopathological features of human
prostate cancer [31,32,33]. More importantly, androgen ablation
of these mice by surgical castration led to the emergence of ADI
prostate cancer growth (Figure 4A) [33]. Recently, prostate cancer
cell lines were established from primary prostate cancers of the Pten
deletion model [34]. After long-term culture of these cells under
androgen-depleted conditions, ADI prostate cancer-like cells
designated as ‘‘E’’ cells evolved following an initial massive cell
death of AD cells. Additionally, prostate cancer cell lines were also
established from recurrent ADI prostate cancer that developed
after surgical castration and named ‘‘CE’’ cells [34]. Unlike the E
cells, these CE cell lines are androgen depletion-independent from
the beginning such that there was no initial massive cell death
under androgen-depleted conditions. To investigate whether TPL2
activation is physiologically relevant to ADI tumor growth in vivo,
we first compared the expression levels of TPL2 between E cell
lines (E2 and E4) and CE cell lines (CE1, CE2, and CE3). CE cell
lines (CE1, CE2, and CE3) showed higher levels of TPL2
expression compared to E cell lines (E2 and E4) by western blot
and immunohistochemistry (Figure 4B and 4C). Interestingly, E
cell lines showed slightly higher levels of AR expression than CE
cell lines, suggesting that E cell lines may have acquired ADI
growth though AR overexpression (Figure 4B). The ADI cell
growth of CE cells (CE1, CE2, and CE3) was more notably
impacted than E cells (E2 and E4) when treated with increasing
levels of a TPL2 inhibitor (Figure 4D). Collectively, these
observations suggest that TPL2 is also required for efficient ADI
prostate cancer cell growth in the mouse model.
TPL2 expression is upregulated in human ADI prostate
cancer specimens
Finally, to validate the clinical relevance of TPL2 kinase action
in human ADI prostate cancer growth, we examined the
frequency of TPL2 expression in ADI human prostate cancer
specimens using tissue microarrays (TMA). We evaluated the
TPL2 immunostaining of 12 normal (N), 52 hormone-naı ¨ve (HN),
52 hormone-refractory (HR), 26 hormone-naı ¨ve metastatic (HN
Met), and 12 hormone-refractory metastatic (HR Met) formalin
fixed paraffin embedded samples. Figure 5A shows representative
photos of the TPL2 expression of normal prostate, hormone-naive
prostate cancer, and hormone-refractory prostate cancer human
prostate TMA samples. As shown in Figure 5B, the overall staining
frequency of TPL2 increased in hormone-naı ¨ve (34.8%) and
hormone-refractory (36.5%) samples in comparison to normal
prostate samples (18.2%). The increases are more significant in
metastatic prostate cancer samples with 46.2% (p,0.05) of
hormone-naı ¨ve metastatic and 41.7% of hormone-refractory
metastatic samples, suggesting that TPL2 expression may also be
associated with prostate cancer metastasis. In particular, both the
overall mean staining score and the frequency of samples with a
strong straining score increased with the progression of prostate
cancer (Figure 5B). Taken together, these TMA data suggest that
TPL2 expression is upregulated with the progression of prostate
cancer.
Discussion
Prostate cancer can easily be treated and cured if it is detected
in its early stages, when tumor growth is still confined to the
prostate. However, once the cancer spreads beyond the prostate
gland, treatment becomes difficult, although treatment options,
such as radiation therapy, hormone therapy, and chemotherapy
are used with varying degrees of effectiveness. The emergence of a
more aggressive, androgen depletion-independent (ADI) form of
prostate cancer is complication frequent occurrence and reason for
failure of hormone therapy. Therefore, studies associated with the
identification and characterization of the genetics underlying ADI
prostate cancer growth are critical for future developments of
target-driven therapeutic strategies for the efficient treatment of
ADI prostate cancer. In this study, by screening a library of
activated human kinases, we identified and characterized a kinase
gene, TPL2, that appears to drive ADI prostate cancer growth.
More importantly, TPL2 is upregulated in ADI prostate cancers of
both the Pten deletion mouse model and the clinical prostate
Figure 2. Induction of ADI prostate cancer cell growth by TPL2
activation. (A) Schematic of established stable LNCaP cell lines
overexpressing either GFP, a myc-tagged wild-type TPL2 [myc-TPL2
(WT)], a myc-tagged constitutively activated form of TPL2 with a
truncation of 70 amino acids in its C-terminus [myc-TPL2 (DC)], or a myc-
tagged kinase-inactive form of TPL2 [myc-TPL2 (D270A)] using the
pBabe-puro expression vector. (B) Western blot analysis to detect the
expression of the TPL2 constructs above (as indicated with arrows in
red). b-actin was used as a control for loading the same amount of
proteins. (C) MTT assays to measure cell proliferation of the stable cell
lines above in the absence or with low levels of R1881 (0.01 nM, 0.1 nM,
and 1 nM). Statistically significant increases in cell proliferation in
comparison to control cells (LNCaP-GFP) are marked with * (p,0.05).
doi:10.1371/journal.pone.0016205.g002
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plays a critical role in the promotion of ADI prostate cancer
progression.
TPL2, also known as tumor progression locus 2, encoding a
product with a deletion of its C-terminal region was initially cloned
as a transforming gene from a human thyroid carcinoma cell line,
and it was called cot (cancer Osaka thyroid) [35]. Almost at the
same time, it was also identified as a protein kinase associated with
the development of T-cell lymphoma, when it was discovered that
the Moloney murine leukemia proviral genome had integrated
into the last intron of the TPL2 gene resulting in a deletion of its C-
terminal [36]. A transgenic mouse study showed that only
transgenic mice expressing a C-terminal deleted form of TPL2
under the control of a proximal Lck promoter developed T-cell
lymphoma, suggesting that the C-terminal domain of wild-type
TPL2 plays an inhibitory role in its kinase activity [37]. In fact, the
C-terminal deleted TPL2 has increased stability and a higher
specific kinase activity than wild-type. In addition, TPL2 interacts
with a negative regulator, the NF-kB-inhibitory protein NF-kB1
p105 through its C-terminus, and thus the C-terminal deleted
TPL2 is insensitive to p105 negative regulation [38,39]. Interest-
ingly, TPL2 expression is also upregulated in approximately 40%
of human breast cancer specimens, which may be caused by an
increase in TPL2 gene copy numbers [40]. Therefore, it is
important to determine whether TPL2 signaling activation in
human prostate cancer samples may be due to either the genetic
mutation at a C-terminal region or a gene copy number increase.
Our data showed that TPL2 is expressed at higher level in ADI-
C4-2B cells than in AD-LNCaP cells, thereby contributing to the
high endogenous level of ADI transcriptional activation of the PSA
enhancer/promoter cis-regulatory region in the ADI-C4-2B cells
(Figure S1). We also compared the TPL2 sequences of two cell
lines, but did not detect any sequence difference, suggesting that
the ADI phenotype of C4-2B cells is not associated with specific
mutations at the TPL2 gene. In addition, a previous study showed
that the mRNA level of TPL2 in the mouse prostate increased after
surgical castration, but it subsequently decreased after re-
administration of testosterone [41]. These microarray data suggest
that TPL2 expression in the prostate is inversely regulated by
testosterone at the transcriptional level. Therefore, it is possible
that decreased level of androgen with hormone therapy may
increase TPL2 expression, resulting in prostate cancer cell survival
and proliferation under androgen-depleted conditions. This
hypothesis is under an active investigation.
In the presence of androgen, AR undergoes phosphorylation,
dimerization, and translocation into the nucleus, wherein it binds
Figure 3. Inhibition of ADI prostate cancer cell growth by TPL2 suppression. (A) Western blot analysis to show the amount of TPL2
expression in the stable C4-2B cell lines expressing the indicated shRNAs using the pLKO.1-TRC lentiviral vector at the time of the following MTT
assay. b-actin was used as a control for loading the same amount of proteins. (B) MTT assays to measure cell proliferation of the stable cell lines in the
absence of R1881. * P,0.05. (C) MTT assays to measure cell proliferation of androgen depletion-independent C4-2B cells with the treatment of TPL2
inhibitor (4 mM). (D) The suppression of MEK/ERK pathway in ADI-C4-2B cells with increasing concentration of a TPL2 inhibitor was confirmed by
western blot.
doi:10.1371/journal.pone.0016205.g003
TPL2 Induces ADI Prostate Cancer Growth
PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e16205to ARE sites, resulting in the transcriptional activation of target
genes [8]. However, several reports indicate that AR is still
necessary for ADI prostate cancer growth [9,10]. As for the
underlying mechanisms of TPL2-mediated ADI prostate cancer
growth, a question is whether this action requires AR expression
and activity. The abrogation of TPL2-mediated PSA promoter
activation in AR-negative DU-145 prostate cancer cells suggests
that TPL2-mediated ADI prostate cancer growth may be still
dependent on AR activity. However, this notion may be more
complex since because DU-145 cells also lack co-regulatory factors
associated with the AR signaling [42]. To determine whether AR
is required for TPL2-mediated transcriptional activation of the
PSA enhancer/promoter cis-regulatory region under androgen-
depleted conditions, we suppressed AR expression by shRNA-
mediated knockdown. Importantly, as shown in Figure S5, the
decreased expression of AR is correlated with decreasing TPL2-
mediated ADI transcriptional activation of the PSA enhancer/
promoter cis-regulatory region. Therefore, TPL2-mediated ADI
transcriptional activation of the PSA enhancer/promoter cis-
regulatory region is AR-dependent. These data suggest TPL2
activation induces AR function under androgen-depleted condi-
tions, possibly through post-translational modifications, such as
phosphorylation. Activated TPL2 kinase itself or its downstream
kinases may phosphorylate AR, which induces the dimerization
and nuclear translocation of AR, and ultimately activates its target
gene expressions for ADI prostate cancer cell growth. On the
other hand, it would also be interesting to investigate whether
TPL2-mediated ADI prostate growth is due to the epigenetic
modulation of androgen-responsive genes by TPL2 in the absence
of androgen, as TPL2 phosphorylates the histone H3 to induce
epigenetic alteration and thereby cell growth transformation
[43,44].
Figure 4. TPL2 activation in ADI prostate cancer of the Pten deletion mouse model. (A) Schematic of the ‘‘Pb-Cre4::Pten
f/f::b-Actinp-GFP
f/f-
Luc’’ mouse model, in which Pten alleles are homozygously deleted and Luciferase is expressed in the prostate epithelium by the prostate-specific
Probasin promoter (Pb)-driven Cre recombinase expression. These compound mice developed prostate Intraepithelial neoplasia (PIN), prostatic
invasive adenocarcinoma, and metastatic prostate cancer at the indicated times. Most importantly, androgen ablation of these mice by surgical
castration led to the emergence of ADI prostate cancer growth at times varying from 7 to 28 weeks post-castration in all living mice. E2 and E4
prostate cancer cell lines were established initially from primary prostate cancer cells before castration that later evolved ADI growth upon long-term
culture under androgen-depleted conditions. However, CE1, CE2, and CE3 prostate cancer cell lines were established from ADI prostate cancers after
castration. Photos (200X) are representative of cell morphologies of E2 and CE1 cells. (B) Western blot analysis to compare the expression levels of AR
and TPL2 between E cell lines (E2 and E4) and CE cell lines (CE1, CE2, and CE3) cells. b-actin was used as a control for loading the same amount of
proteins. AD, androgen-dependent; ADI, androgen depletion-independent; and AR, androgen receptor. (C) Immunohistochemical analysis to examine
TPL2 expression in AD and ADI prostate cancers of the Pten deletion mouse model. Human duodenum tissue expressing high levels of endogenous
TPL2 was used as a positive control (upper right). As a negative control, the tissue was stained only with the secondary antibody (upper left). Pca,
prostatic adenocarcinoma. (D) MTT assays to measure cell proliferation of E cells (E2 and E4) and CE cells (CE1 and CE3) with the treatment of different
levels of TPL2 inhibitor (0, 1, 5, or 10 mM). Statistically significant decreases in cell proliferation in comparison to vehicle treatment are marked with
*( p ,0.05).
doi:10.1371/journal.pone.0016205.g004
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major factor influencing prostate cancer, although the etiological
agents of prostatic inflammation remain controversial [45].
Recently, genetically-engineered mouse studies clearly shows that
an inflammatory cytokine, a lymphotoxin produced by B cells
which have infiltrated the site of regressing AD prostate cancer
after castration, promotes ADI prostate cancer [46]. It has also
been shown that Toll-like receptor 4 (TLR4) is expressed in the
prostate gland and its expression is closely associated with the
severity of prostate cancer [47]. Therefore, these data support a
connection between the activation of the TPL2 signaling pathway
and inflammatory responses in the development prostate cancer.
Furthermore, epidemiological studies have suggested that expo-
sure to inorganic arsenite is an important environmental risk factor
of human prostate cancer [48]. Importantly, TPL2 has been
identified as a key regulator of arsenite-induced signal transduction
[49]. Thus, future study will be directed to investigate the role of
TPL2-mediated inflammatory signal transduction in ADI prostate
cancer development.
Functionally, TPL2 activation induces ERK, JNK, and NF-kB
signaling pathways in both stimulus- and cell type-specific manners
[38,50]. The treatment of a MEK inhibitor, U0126, significantly
diminished TPL2-mediated transcriptional activity of the PSA
enhancer/promoter cis-regulatory region reporter construct under
androgen-depleted conditions (Figure S6). In addition, either
overexpression of a dominant-negative mutant form of IkBa,I kBa
(32/36AA) denoted as IkBa DN, or treatment of a IKK inhibitor,
PS-1145, diminished the PSA transcriptional activity (Figure S7).
Together, these data suggest that the activation of both the MEK/
ERK pathway and NF-kB signaling pathway is required for
TPL2-mediated ADI prostate cancer growth. Therefore, we
propose that a combination targeting both the TPL2/MEK/
ERK pathway and the RAS/RAF/MEK/ERK pathway may
potentially lead to new therapeutic intervention strategies of ADI
prostate cancer (Figure S8).
Materials and Methods
Screening of a Library of Activated Human Kinases
The library of 354 human kinases contains 98 kinase-related
open reading frames (ORFs) and 256 human kinases cloned into a
Gateway-compatible retroviral destination vector, pWN-MF-
DEST, in which a myr sequence and a flag-epitope tag (MF)
were added to the N-termini of each introduced ORF [27]. 1 mg
DNA of each kinase construct, along with 0.5 mg DNA of a
reporter plasmid containing the 5.8 kb enhancer/promoter region
of the PSA gene (PSA-enhancer/promoter-Luc), were co-trans-
fected into individual wells of a 12-well plate containing 2610
5
androgen-dependent LNCaP (AD-LNCaP) cells using Lipofecta-
mine
TM LTX (3 ml of Lipofectamine LTX+1 mlo fplus reagent in
100 ml opti-MEM for each transfection; Invitrogen). 24 hours after
transfection, the media was changed with 10% charcoal-stripped
FBS (CS-FBS) with/without R1881, a synthetic androgen.
Relative LUC activity (the PSA-enhancer/promoter-luciferase
activity normalized to the pGL3-beta-galactosidase activity) was
measured after 24 hours of further incubation using Dual-
Figure 5. TPL2 upregulation in ADI human prostate cancer specimens. (A) Representative photos of each normal prostate (N), hormone-
naı ¨ve prostate cancer (HN), hormone-refractory prostate cancer (HR), hormone-naı ¨ve metastatic prostate cancer (HN Met), and hormone-refractory
metastatic prostate cancer (HR Met) of the stained human prostate tissue microarrays. TPL2 expression was detected by immunohistochemical
analysis using an antibody against TPL2. (B) Statistical analysis of TPL2 expression in each group of N, HN, HR, HN Met, HR Met samples of the stained
human prostate tissue microarrays in terms of mean staining scores and staining percentage. Statistically significant differences in mean staining
score is marked with * (p,0.05). Total sample numbers for each group are noted. Staining intensity was scored independently by two urologic
pathologists with 0 (no staining), 1 (weak staining), 2 (intermediate staining), and 3 (strong staining) for each sample.
doi:10.1371/journal.pone.0016205.g005
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Enzyme Assay System (Promega). All the transfections were
performed independently twice.
Cell Lines, Vectors, and Retroviral/Lentiviral Infection
293T cells and LNCaP cells were obtained from ATCC
(Manassas, VA). C-2B cells, previously established from LNCaP
cells [51], were kindly provided by Dr. Roy-Burman. We first
established AD-LNCaP stable cell lines that over-express either a
N-terminally myc-tagged wild-type [myc-TPL2 (WT)], a N-
terminally myc-tagged constitutively activated form with a deletion
of 70 amino acids in C-terminus [myc-TPL2 (DC)], or a N-
terminally myc-tagged kinase-inactive form of TPL2 [myc-TPL2
(D270A)] using a pBabe-puro retroviral expression vector. 293T
cells (4610
6 cells per 10 Cm dish) were transfected with 5 mgo f
each expression vector and 5 mg of packaging vector (pCL) using
the CalPhos
TM Mammalian Transfection Kit (Clontech). After
6 hours, the media was changed, and the medium containing the
recombinant viruses was collected at 48 and 72 hours post
transfection for two independent infections. For each infection,
the collected media was filtered through a 0.45 mm filter to remove
cell debris and then equal amounts of fresh RPMI supplemented
with 10% FBS was mixed with the filtered media with 8 mlo f
polybrene (1 mg/L) per 10 ml medium. 24 hours after the second
infection, infected cells were selected for one week with puromycin
(1 mg/ml). The established cell lines were then checked for TPL2
expression by western blot using an antibody against TPL2.
Another set of AD-LNCaP stable cell lines that over-express either
a C-terminally flag-tagged wild-type (TPL2-wt-flag), a C-termi-
nally flag-tagged constitutively activated form with a deletion of 70
amino acids in C-terminus (TPL2-delC-flag), or a C-terminally
flag-tagged kinase-inactive form of TPL2 (TPL2-inactive-flag) were
established using a pEF-IRES-puro expression vector. Each
construct (5 mg) was transiently transfected into LNCaP cells
using the Lipofectamine
TM LTX with Plus
TM Reagent (Invitro-
gen), and transfected cells were selected for one month with
puromycin (1 mg/ml). For shRNA-mediated knockdown, we
established two sets of ADI-C4-2B stable cell lines that express
either shRNA-control or shRNA-TPL2 using both the pGIPZ
lentiviral vector and the pLKO.1-TRC lentiviral expression
vector. In brief, 7.5 mg of pCMV-dR8.2 dvpr (Addgene) and
3 mg of pCMV-VSV-G (Addgene) packaging vectors were used
with 10 mg of lentiviral expression vector for transfection into
293T cells. We used three different antibodies to detect TPL2. An
antibody that detects an N-terminal epitope of TPL2 (Cot [N-17],
catalog # sc-1717, Santa Cruz INC. with 1:500 dilution) was used
for the detection of TPL2 expression by western blot in Figure 2B,
Figure 4B, Figure S2B, and Figure S3A. An antibody that detects
an C-terminal epitope of TPL2 (Cot [M-20], catalog # sc-720,
Santa Cruz INC. with 1:500 dilution) was also used for the
detection of TPL2 expression by western blot in Figure 3A and
Figure S1. An antibody that detects phosphorylated Threonine at
the 290 site of TPL2 (MAP3K8 [phospho T290], catalog #
ab51214, abcamH with 1:200 dilution) was used by western blot in
Figure S2B. Also, we purchased a TPL2 inhibitor and a MEK
inhibitor (U0126) from Calbiochem (Cat. No. 616373) and Cell
Signaling Technology (Cat. No. 9903), respectively.
MTT Assay
The number of viable cells in proliferation was measured
according to the manufacture’s protocol using the CellTiter 96H
AQueous One Solution Cell Proliferation Assay (Promega). 5,000
cells in a volume of 200 ml were seeded in an individual well of 96-
well plates.
Immunohistochemical Analysis
TMAs composed of 11 cases of normal prostate, 52 cases of
hormone-naı ¨ve human prostate cancer tissue, 52 cases of
hormone-refractory prostate cancer tissue, 26 cases of hormone-
naı ¨ve metastatic prostate cancer tissue, and 12 cases of hormone-
refractory metastatic prostate cancer tissue were obtained from the
New York University (NYU) Prostate Cancer Tissue Resource.
The TMAs were incubated in pre-boiled citrate buffer (0.01 M,
PH 6.4) and left until they reached room temperature (R.T.) for
antigen retrieval, and immunostained with a TPL2 antibody (Cot
(M-20) #sc-720; Santa Cruz Biotechnology Inc.; 1:200 dilution).
As a positive control, human duodenum tissue samples were used
to optimize staining conditions. The staining was reviewed and
expression of TPL2 scored for intensity and proportion by Dr.
Jonathan Melamed at NYU.
Supporting Information
Figure S1 Higher level of TPL2 expression in ADI-C4-2B
cells than AD-LNCaP cells. (A) Western blot analysis was
performed to compare the level of TPL2 expression between AD-
LNCaP cells and ADI-C4-2B cells (three different passages for each
cell line). b-actin was used as a control for loading the same amount
of proteins. (B) The PSA enhancer/promoter activity in response to
overexpression of exogenous TPL2 in ADI-C4-2B cells. Relative
LUC activities were measured with increasing concentration of
TPL2 expression vector in ADI-C4-2B cells. All the experiments
wereperformedthreetimeswith each intriplicate,andeach column
represents the mean 6 standard deviation.
(TIF)
Figure S2 Induction of ADI prostate cancer cell growth
by TPL2 activation. (A) Schematic of established stable LNCaP
cell lines overexpressing either a C-terminally flag-tagged wild-type
TPL2 (TPL2-wt-flag), a C-terminally flag-tagged constitutively
activated form of TPL2 with a truncation of 70 amino acids in its
C-terminus (TPL2-delC-flag), or a C-terminally flag-tagged kinase-
inactive form of TPL2 (TPL2-inactive-flag) using the pEF-IRES-
puro expression vector. (B) Western blot analysis to detect the
expression of TPL2 and its downstream signaling molecules. TPL2
(N-terminal), TPL2 (C-terminal), and TPL2 (phospho-270) expres-
sion detected by different antibodies that specifically recognize a N-
terminal epitope, a C-terminal epitope, or phopsphorylation at
Threonine 290 of TPL2 (as indicated with arrows in red),
respectively. b-actin was used as a control for loading the same
amount of proteins. (C) MTT assays to measure cell proliferation of
the stable cell lines above in the absence of R1881. Increased cell
proliferationof C4-2B (vector), LNCaP(TPL2-wt-flag), and LNCaP
(TPL2-delC-flag) cells under androgen-depleted conditions at 2, 4,
6, and 8 days are all statistically significant in comparison to the cell
proliferation of LNCaP (vector) cells (* p,0.05).
(TIF)
Figure S3 Inhibition of ADI prostate cancer growth by
TPL2 suppression. (A) Western blot analysis to show the levels
of TPL2 expression in the stable C4-2B cell lines expressing the
indicated shRNAs using a pGIPZ lentiviral expression vector at
the time of the following MTT assay. The number indicates
different shRNA clones targeting the same gene. Because TPL2/
MAP3K8 is a MAP3K (mitogen-activated protein kinase kinase
kinase), two other MAP3Ks, MAP3K6 (mitogen-activated protein
kinase kinase kinase 6) and MAP3K14 (mitogen-activated protein
kinase kinase kinase 14) were used as controls for off-target effects.
b-actin was used as a control for loading the same amount of
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stable cell lines expressing either shRNA (#4) targeting TPL2,
which showed efficient knockdown of TPL2 expression above, or
control shRNA under androgen-depleted conditions. Cell prolif-
eration of C4-2B stable cells expressing shRNA (#4) targeting
TPL2 significantly decreased in comparison to control cells on the
indicated days (* p,0.05).
(TIF)
Figure S4 Determination of the 50% inhibitory concen-
tration (IC
50) of a TPL2 inhibitor. MTT assays measuring
the cell proliferation of ADI-C4-2B cells in the absence of R1881
with increasing concentration of the TPL2 inhibitor were
performed to determine the 50% inhibitory concentration (IC
50)
of a TP2 inhibitor. After 24 hours of TPL2 inhibitor treatment at a
concentration of 4 uM, cell proliferation of ADI-C4-2B cells was
suppressed by 50% in comparison to no treatment. The same
concentrations of vehicle (DMSO) were treated in parallel as
controls.
(TIF)
Figure S5 TPL2-mediated ADI transcriptional activa-
tion of the PSA enhancer/promoter cis-regulatory
region is AR-dependent. Relative LUC activities were
measured under androgen-depleted conditions with increasing
amount of sh-RNAs targeting AR. AD-LNCaP cells were
transiently co-transfected with a reporter plasmid (the PSA
enhancer/promoter cis-regulatory region reporter construct), a
plasmid expressing a constitutively activated form of TPL2
(myristoylated TPL2), and the indicated sh-RNAs. Western blot
analysis shows the amount of AR expression at the time of the
Luciferase assay. b-actin was used as a control for loading the same
amount of proteins. Statistically significant decreases in LUC
activities in comparison to that of TPL2-mediated ADI trans-
criptional activation (0 nM R1881+TPL2) are marked with
*( p ,0.05).
(TIF)
Figure S6 The activation of MEK/ERK pathway is
required for TPL2-mediated ADI prostate cancer growth.
(A) Relative LUC activities were measured with increasing
concentration of a MEK inhibitor (U0126) in AD-LNCaP cells
that were transiently co-transfectedwitha reporter plasmid (the PSA
enhancer/promoter cis-regulatory region reporter construct) and a
plasmid expressing a constitutively activated form of TPL2
(myristoylated TPL2). Relative LUC activities with the transfection
of a vector control with/without R1881 are indicated in black bars.
All the experiments were performed three times with each in
triplicate, and each column represents the mean 6 standard
deviation. Statistically significant decreases in LUC activities in
comparison to vehicle treatment are marked with * (p,0.05). (B)
Western blot analysis shows the inhibition of ERK/MEK pathway
in LNCaP cells with increasing amount of U0126 treatment.
(TIF)
Figure S7 The activation of NF-kB pathway is also
required for TPL2-mediated ADI prostate cancer
growth. (A) and (B) Relative LUC activities were measured with
increasing concentration of either a dominant-negative mutant
form of IkBa,I kBa (32/36AA) deonoted as IkBa DN, or a IKK
inhibitor, PS-1145. In AD-LNCaP cells, reporter plasmids (NF-kB
promoter-Luc or PSA enhancer/promoter-Luc) were transiently
co-transfected with either a plasmid expressing a constitutively
activated form of TPL2 (myristoylated TPL2) or control vector.
Statistically significant decreases in LUC activities with increasing
amount of IkBa DN in comparison to vector control with TPL2
expression (the third column) are marked with * (p,0.05). In ADI-
C4-2B cells, only the reporter plasmids were transfected. All the
experiments were performed three times with each in triplicate,
and each column represents the mean 6 standard deviation.
Statistically significant decreases in LUC activities with increasing
amount of IkBa DN in comparison to vehicle treatment are
marked with * (p,0.05). (C) MTT assays measuring the cell
proliferation of indicated cells in the absence of R1881 with the
treatment of PS-1145 (10 uM) were performed. Statistically
significant decreases in cell proliferation in comparison to mock
treatment are marked with * (p,0.05).
(TIF)
Figure S8 Alternative activation of the MEK/ERK
pathway and NF-kB by TPL2 contribute to ADI prostate
cancer cell growth. Previously, it has been shown that
activation of AKT and ERK MAP kinase signaling pathways
synergistically promote in vivo ADI prostate cancer growth,
possibly through the activation of growth factors/receptor tyrosine
kinase (RTK)/RAS pathway by autocrine and paracrine growth
factor loops [38]. Here, we found TPL2 contribute to ADI
prostate cancer growth through the alternative activation of
MEK/ERK pathway and NF-kB. Therefore, our findings may
potentially lead to new therapeutic intervention strategies for the
treatment of ADI prostate cancer, such as a combination therapy
targeting both TPL2 activation and the RAS/RAF/MEK/ERK
pathway for example. RTK, receptor tyrosine kinase; SHC, Src
homology 2 domain containing transforming protein; GRB 2,
growth factor receptor bound 2; GEF, guanine nucleotide
exchange factor; GAP, GTPase activating protein.
(TIF)
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